In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

KAI licenses cardiovascular candidate to Sankyo; deal ended

Executive Summary

KAI Pharmaceuticals Inc. (develops activators and inhibitors of protein kinase C for cardiovascular diseases) licensed Sankyo Co. Ltd. (the Sankyo part of the recent Daiichi Sankyo merger) worldwide development and commercialization rights to the delta protein kinase C (PKC) inhibitor KAI9803.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Terminated
Deal Type
  • Alliance
    • Co-Promotion
    • Includes Royalty or Profit Split Information
    • R&D and Marketing (Licensing)

Related Companies